Your browser doesn't support javascript.
loading
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Shah, Manish A; Shitara, Kohei; Ajani, Jaffer A; Bang, Yung-Jue; Enzinger, Peter; Ilson, David; Lordick, Florian; Van Cutsem, Eric; Gallego Plazas, Javier; Huang, Jing; Shen, Lin; Oh, Sang Cheul; Sunpaweravong, Patrapim; Soo Hoo, Hwoei Fen; Turk, Haci Mehmet; Oh, Mok; Park, Jung Wook; Moran, Diarmuid; Bhattacharya, Pranob; Arozullah, Ahsan; Xu, Rui-Hua.
Afiliação
  • Shah MA; Weill Cornell Medical College, New York City, NY, USA.
  • Shitara K; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa City, Japan.
  • Ajani JA; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bang YJ; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Enzinger P; Center for Esophageal and Gastric Cancer, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ilson D; Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
  • Lordick F; Department of Medicine and University Cancer Center Leipzig, University of Leipzig Medical Center, Leipzig, Germany.
  • Van Cutsem E; Digestive Oncology, University Hospitals Gasthuisberg, Leuven and KULeuven, Leuven, Belgium.
  • Gallego Plazas J; Department of Medical Oncology, Hospital General Universitario de Elche, Elche, Spain.
  • Huang J; Department of Medical Oncology, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Shen L; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
  • Oh SC; Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Sunpaweravong P; Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  • Soo Hoo HF; Department of Oncology and Radiotherapy, Penang Hospital, Penang, Malaysia.
  • Turk HM; Department of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
  • Oh M; Astellas Pharma Global Development, Inc., Northbrook, IL, USA.
  • Park JW; Astellas Pharma Global Development, Inc., Northbrook, IL, USA.
  • Moran D; Astellas Pharma Global Development, Inc., Northbrook, IL, USA.
  • Bhattacharya P; Astellas Pharma Global Development, Inc., Northbrook, IL, USA.
  • Arozullah A; Astellas Pharma Global Development, Inc., Northbrook, IL, USA.
  • Xu RH; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China. xurh@sysucc.org.cn.
Nat Med ; 29(8): 2133-2141, 2023 08.
Article em En | MEDLINE | ID: mdl-37524953
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article